TY - JOUR
T1 - Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria
T2 - Results of a bone marrow failure consortium study
AU - Nyland, Susan Bell
AU - Krissinger, Daniel J.
AU - Clemente, Michael J.
AU - Irby, Rosalyn B.
AU - Baab, Kendall Thomas
AU - Jarbadan, Nancy Ruth
AU - Sokol, Lubomir
AU - Schaefer, Eric
AU - Liao, Jason
AU - Cuthbertson, David
AU - Epling-Burnette, Pearlie
AU - Paquette, Ronald
AU - List, Alan F.
AU - Maciejewski, Jaroslaw P.
AU - Loughran, Thomas P.
N1 - Funding Information:
The project described was supported by Grant Number U54RR019397 , “Bone Marrow Failure Clinical Research Center” to J.M., Cleveland Clinic Award #5401 to T.P.L., “Longitudinal Studies in Bone Marrow Failure Diseases” , and a pilot project award #5409 , “HTLV-2 Seroreactivity in LGL Leukemia” to T.P.L., all from the NIH Rare Diseases Clinical Research Network . Additional support for this work was obtained from NIH funding. NCI Grants CA133525 and CA 94872 were awarded to T.P.L. NCI Grant CA112112 was awarded to P.E.B. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH Rare Diseases Clinical Research Network.
PY - 2012/5
Y1 - 2012/5
N2 - Large granular lymphocyte (LGL) leukemia is characterized by clonal expansion of antigen-activated cytotoxic T cells (CTL). Patients frequently exhibit seroreactivity against a human T-cell leukemia virus (HTLV) epitope, BA21. Aplastic anemia, paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome are bone marrow failure diseases that can also be associated with similar aberrant CTL activation (LGL-BMF). We identified a BA21 peptide that was specifically reactive with LGL leukemia sera and found significantly elevated antibody reactivity against the same peptide in LGL-BMF sera. This finding of shared seroreactivity in LGL-BMF conditions and LGL leukemia suggests that these diseases might share a common pathogenesis.
AB - Large granular lymphocyte (LGL) leukemia is characterized by clonal expansion of antigen-activated cytotoxic T cells (CTL). Patients frequently exhibit seroreactivity against a human T-cell leukemia virus (HTLV) epitope, BA21. Aplastic anemia, paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome are bone marrow failure diseases that can also be associated with similar aberrant CTL activation (LGL-BMF). We identified a BA21 peptide that was specifically reactive with LGL leukemia sera and found significantly elevated antibody reactivity against the same peptide in LGL-BMF sera. This finding of shared seroreactivity in LGL-BMF conditions and LGL leukemia suggests that these diseases might share a common pathogenesis.
UR - http://www.scopus.com/inward/record.url?scp=84858748852&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858748852&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2012.02.001
DO - 10.1016/j.leukres.2012.02.001
M3 - Article
C2 - 22386729
AN - SCOPUS:84858748852
SN - 0145-2126
VL - 36
SP - 581
EP - 587
JO - Leukemia Research
JF - Leukemia Research
IS - 5
ER -
